New drug duo aims to stop deadly rebleeding in liver patients
NCT ID NCT07465471
Summary
This study aims to see if adding a blood pressure medication called midodrine to a standard liver drug (carvedilol) works better than carvedilol alone to prevent a second, dangerous bleeding episode in people with advanced liver cirrhosis. It will enroll 210 patients in India who have just survived a first major bleed. Researchers will follow participants for six weeks to see which group has fewer repeat bleeds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.